🧾 What This Document Is

This is an 8-K filing, which is a report of unscheduled, material events that a public company must file with the SEC. It includes a press release with two main things: their financial results for the last quarter and year (Q4 and full-year 2025), and a major business update about searching for a buyer or partner.

👉 Why it matters: This isn't just a routine earnings report. The announcement that they are exploring "strategic alternatives" is the biggest news here, signaling a potential major change for the company's future.

🏢 What The Company Does

In simple terms, ENDRA Life Sciences is a small medical technology company developing a handheld ultrasound device called TAEUS®. Its goal is to measure fat in the liver to help diagnose and monitor widespread conditions like Steatotic Liver Disease (SLD), which affects billions of people globally. They aim to provide a cheaper, more accessible alternative to the current gold-standard MRI test.

🚀 Key Moves: A Pivotal Moment

This section covers the two most critical updates from the filing.

🔍 Searching for a Buyer or Partner

On March 25, 2026, ENDRA's Board started a formal process to explore "strategic alternatives." This is corporate-speak for looking to be acquired, merge with another company, or find a major strategic partner. They have no set deadline and will keep running the business as usual during this search.

👉 Why it matters: This is often a sign that a company believes it can create more value for shareholders through a deal than by continuing alone. Given their cash position (see below), it suggests they are seeking resources to bring their product to market.

🧪 Strong Clinical Progress with TAEUS®

Throughout late 2025 and early 2026, the company released several positive studies on its redesigned TAEUS Liver device:

• Accurate: Showed a strong correlation (r=0.89) with MRI for measuring liver fat.
• Precise: Demonstrated reliable results when used by different operators (ICC of 0.89).
• Useful: Positioned the tool as potentially valuable for both routine doctor's visits and pharmaceutical company clinical trials.

👉 Why it matters: This clinical data is the company's main asset. It's designed to prove to potential buyers, partners, and regulators that their technology works reliably, which is essential for achieving their commercial goals.

💰 Financial Highlights: Shrinking Losses, Low Cash

The numbers show a company that has significantly cut costs but is burning through its remaining cash.

• Operating Expenses (2025): $5.8 million, down sharply from $10.8 million in 2024. This shows strict cost-cutting.
• Net Loss (2025): $7.0 million, an improvement from the $11.5 million loss in 2024.
• Cash & Digital Assets (Dec 31, 2025):
  • Cash: $762,365
  • Digital Assets (like crypto): $2,009,960
  • Total Liquid Assets: ~$2.8 million

👉 Why it matters: While losses are down, the cash balance is very low for a company developing a medical device. This cash situation makes the "strategic alternatives" search even more urgent, as they will likely need more funding to commercialize TAEUS.

📦 Financial Position: A Snapshot

This looks at what the company owns and owes at year-end 2025.

• Total Assets: $3.85 million (down from $4.45 million in 2024).
• Total Liabilities: $1.59 million (down from $1.89 million).
• Stockholders' Equity: $2.26 million. The accumulated deficit (total losses over time) is a massive $110.5 million, highlighting the company's early-stage, pre-revenue status.

👉 Why it matters: The balance sheet is small. The decrease in total assets is mainly due to cash being used to fund operations. The company is financing itself through selling stock (notice the large "paid-in capital" figure) and holding digital assets.

💸 Cash Flow Story: Funding the Burn

The filing shows cash "used in operations" was $1.6 million in Q4 2025. This is the actual cash burn rate to keep the lights on and run clinical studies. With only about $2.8 million in combined cash and digital assets at year-end, this burn rate indicates a limited runway without securing additional capital.

🔮 What's Next: The Search is On

The company's immediate future is defined by the strategic review. They will continue their clinical and operational work while engaging with potential acquirers or partners. No timeline is set, creating uncertainty. Their key goal is to translate their positive clinical data into a commercial deal or partnership that can fund the final steps to market.

⚖️ Big Picture: Strengths & Risks

• 👍 Strengths: Clear, positive clinical data validating their technology. A large, underserved target market (liver disease). Significant cost reduction has extended their financial runway.
• ⚠️ Risks: Extremely low cash reserves create financing risk. The "strategic alternatives" process creates uncertainty about the company's independent future. They are not yet generating revenue and face regulatory and commercialization hurdles.

🧠 The Analogy

ENDRA is like a talented chef who has perfected a revolutionary new recipe (TAEUS) and published glowing reviews (clinical data) but has almost no money left to open their own restaurant. Now, they are putting the recipe on the market, looking for an investor or a restaurant chain to buy it and bring it to customers.

📇 Key Contacts & People

• Alexander Tokman: Chief Executive Officer
• Investor Relations: [email protected]
• Investor Relations Contact: Yvonne Briggs, Alliance Advisors IR
  • Phone: (310) 691-7100
  • Email: [email protected]

🧩 Final Takeaway

ENDRA is at a crossroads. It has a promising, clinically validated medical device but very little cash left. Its announcement to explore a sale or partnership is a direct response to this dilemma, making the outcome of this search the single most important factor for the company's future.